期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Printed hole-conductor-free mesoscopic perovskite solar cells with excellent long-term stability using PEAI as an additive 被引量:2
1
作者 Cong Xua Zheling Zhang +4 位作者 Yue Hu Yusong Sheng Pei Jiang Hongwei Han Jian Zhang 《Journal of Energy Chemistry》 SCIE EI CAS CSCD 2018年第3期764-768,共5页
Phenethylamine(PEA) was successfully introduced into hole-conductor-free, fully printable mesoscopic MAPbI3 perovskite solar cells(MPSCs) with a carbon electrode by mixing phenethylammonium iodide with MAPbI3 pero... Phenethylamine(PEA) was successfully introduced into hole-conductor-free, fully printable mesoscopic MAPbI3 perovskite solar cells(MPSCs) with a carbon electrode by mixing phenethylammonium iodide with MAPbI3 perovskite solution. PEA-MAPbI3 films show better pore filling into TiO2 scaffold that forms better contact, and induce longer exciton lifetime and higher quantum efficiency of photoinduced charge separation. As a result, the power conversion efficiency of PEA-MAPbI3 MPSCs is 37% higher than that of MAPbI3 MPSCs. And PEA-MAPbI3 MPSCs show excellent long-term stability that could keep 90% of origin power conversion efficiency for over 80 days in the air. 展开更多
关键词 Phenethylamine Additive Hole-conductor-free Mesoscopic perovskite solar cells Stability
下载PDF
Antiarrhythmic drugs and ventricular defibrillation energy requirements
2
作者 齐向前 《Chinese Medical Journal》 SCIE CAS CSCD 1999年第12期91-96,共6页
Purpose To understand the potential interaction between antiarrhythmic therapy and the implantable cardioverter defibrillator (ICD) in patients who receive pharmacologic therapy as an adjunct to ICD therapy Data so... Purpose To understand the potential interaction between antiarrhythmic therapy and the implantable cardioverter defibrillator (ICD) in patients who receive pharmacologic therapy as an adjunct to ICD therapy Data sources MEDLINE searching was employed and the information was indexed from approximately 3600 journals published world wide from 1966 to 1998 Study selection and data extraction Data were collected from 66 of approximately 455 originally identified articles and abstracts using explicit methodological criteria Results The ICD therapy has been widely used for therapy of life threatening ventricular arrhythmias (VT/VF) and prevention of recurrence of sudden cardiac death Studies reported that 40%-70% or 10%-40% of ICD patients required concomitant antiarrhythmic medication to reduce the frequency of sustained arrhythmic episodes and to minimize the frequency of device discharges Most studies on antiarrhythmic drug ICD interactions have been performed in experimental animals Antiarrhythmic drugs can influence the effectiveness of ICD to terminate arrhythmias through their effects on defibrillation threshold (DFT) Studies have demonstrated a rise in DFTs with class Ib agent lidocaine and class Ic agents encainide and flecainide Class Ia agents, as well as amiodarone, bretylium and propafenone may have more variable effects on DFT probably because of the difference between acute and chronic drug dosing, dose related changes, active metabolites, and reproducibility in determining DFT Class Ⅲ agents, with the exception of amiodarone, consistently decrease DFT These drugs can be used as front line agents in ICD patients Conclusions Antiarrhythmic drugs can increase, decrease, or have no effect on DFT Class Ⅲ agents except amiodarone can be safely administered in conjunction with ICD patients as long as the interaction between these therapeutic modalities is appreciated 展开更多
关键词 Defibrillators Implantable ANIMALS Anti-Arrhythmia Agents Humans phenethylamines SOTALOL SULFONAMIDES Ventricular Fibrillation
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部